Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma

Exclusion Criteria

• •Planned concomitant systemic anti-tumor therapy during intraperitoneal treatment;
• •Massive ascites not expected to be adequately drained prior to dosing;
• •Chemotherapy or radiotherapy within 4 weeks prior to enrollment (≥ 6 weeks for nitrosoureas or mitomycin C);
• •Pregnancy or lactation, or unwillingness to use effective contraception;
• •Severe abdominal infection or gastrointestinal obstruction;
• •Known peritoneal adhesions deemed unsuitable for catheter placement;
• •Active bleeding, uncorrected coagulation disorders, or inability to safely interrupt therapeutic anticoagulation;
• •Known hypersensitivity to PX, nab-paclitaxel, or excipients;
• •Pre-existing ≥ Grade 2 peripheral sensory neuropathy;
• •Severe or uncontrolled comorbidities that may increase study risk or interfere with evaluation;
• •Active or severe autoimmune disease, or ongoing systemic immunosuppressive therapy;
• •Positive for HBsAg, anti-HCV, syphilis antibody, or HIV antibody;
• •Psychiatric or cognitive disorders affecting compliance;
• •Any other condition deemed unsuitable by the investigator.